Michael C. Bassik

Michael C. Bassik

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Michael C. Bassik

Stanford Univeristy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
KHKyuho Han
Kyuho Han
EJEdwin E Jeng
Edwin E Jeng
GHGaelen T Hess
Gaelen T Hess
DMDavid W Morgens
David W Morgens
ALAmy Li
Amy Li
MBMichael C Bassik
Michael C Bassik
An improved strategy for large-scale combinatorial CRISPR screening enables the identification of synergistic drug targets for cancer. Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring method for calculating genetic interactions (GIs) from CRISPR-deleted gene pairs. We applied CDKO to generate a large-scale human GI map, comprising 490,000 double-sgRNAs directed against 21,321 pairs of drug targets in K562 leukemia cells and identified synthetic lethal drug target pairs for which corresponding drugs exhibit synergistic killing. These included the BCL2L1 and MCL1 combination, which was also effective in imatinib-resistant cells. We further validated this system by identifying known and previously unidentified GIs between modifiers of ricin toxicity. This work provides an effective strategy to screen synergistic drug combinations in high-throughput and a CRISPR-based tool to dissect functional GI networks.

3 December 2018 in Nature Genetics
Verified
Journal Article
Open access
JHJeroen R. Huyghe
Jeroen R. Huyghe
SBStephanie A. Bien
Stephanie A. Bien
THTabitha A. Harrison
Tabitha A. Harrison
HKHyun Min Kang
Hyun Min Kang
SCSai Chen
Sai Chen
UPUlrike Peters
Ulrike Peters
To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10-8, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.

31 October 2016 in Nature Methods
Verified
Journal Article
Open access
PDF file
GHGaelen T Hess
Gaelen T Hess
LFLaure Frésard
Laure Frésard
KHKyuho Han
Kyuho Han
CLCameron H Lee
Cameron H Lee
ALAmy Li
Amy Li
MBMichael C Bassik
Michael C Bassik
Recruiting a hyperactive cytidine deaminase via the guide RNA to dCas9 allows for the introduction of diverse point mutations at the CRISPR target locus to create complex libraries of variants for protein engineering or dissection of protein function. Engineering and study of protein function by directed evolution has been limited by the technical requirement to use global mutagenesis or introduce DNA libraries. Here, we develop CRISPR-X, a strategy to repurpose the somatic hypermutation machinery for protein engineering in situ. Using catalytically inactive dCas9 to recruit variants of cytidine deaminase (AID) with MS2-modified sgRNAs, we can specifically mutagenize endogenous targets with limited off-target damage. This generates diverse libraries of localized point mutations and can target multiple genomic locations simultaneously. We mutagenize GFP and select for spectrum-shifted variants, including EGFP. Additionally, we mutate the target of the cancer therapeutic bortezomib, PSMB5, and identify known and novel mutations that confer bortezomib resistance. Finally, using a hyperactive AID variant, we mutagenize loci both upstream and downstream of transcriptional start sites. These experiments illustrate a powerful approach to create complex libraries of genetic variants in native context, which is broadly applicable to investigate and improve protein function.

9 May 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
DMDavid W Morgens
David W Morgens
RDRichard M Deans
Richard M Deans
ALAmy Li
Amy Li
MBMichael C Bassik
Michael C Bassik
A side-by-side comparison of CRISPR/Cas9 and RNAi screens for essential genes reveals method-specific differences in performance. We compared the ability of short hairpin RNA (shRNA) and CRISPR/Cas9 screens to identify essential genes in the human chronic myelogenous leukemia cell line K562. We found that the precision of the two libraries in detecting essential genes was similar and that combining data from both screens improved performance. Notably, results from the two screens showed little correlation, which can be partially explained by the identification of distinct essential biological processes with each technology.

5 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDavid W. Morgens
David W. Morgens
MWMichael Wainberg
Michael Wainberg
EBEvan A. Boyle
Evan A. Boyle
OUOana Ursu
Oana Ursu
CACarlos L. Araya
Carlos L. Araya
MBMichael C. Bassik
Michael C. Bassik
CRISPR-Cas9 screens are powerful tools for high-throughput interrogation of genome function, but can be confounded by nuclease-induced toxicity at both on- and off-target sites, likely due to DNA damage. Here, to test potential solutions to this issue, we design and analyse a CRISPR-Cas9 library with 10 variable-length guides per gene and thousands of negative controls targeting non-functional, non-genic regions (termed safe-targeting guides), in addition to non-targeting controls. We find this library has excellent performance in identifying genes affecting growth and sensitivity to the ricin toxin. The safe-targeting guides allow for proper control of toxicity from on-target DNA damage. Using this toxicity as a proxy to measure off-target cutting, we demonstrate with tens of thousands of guides both the nucleotide position-dependent sensitivity to single mismatches and the reduction of off-target cutting using truncated guides. Our results demonstrate a simple strategy for high-throughput evaluation of target specificity and nuclease toxicity in Cas9 screens.

6 December 2017 in Nature
Verified
Journal Article
Closed access
PDF file
NLNian Liu
Nian Liu
CLCameron H. Lee
Cameron H. Lee
TSTomek Swigut
Tomek Swigut
EGEdward Grow
Edward Grow
BGBo Gu
Bo Gu
JWJoanna Wysocka
Joanna Wysocka